DDReg pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma
Talk To Us

Regulatory

Asserting Patient Rights: The Importance of Labels for Medical Device Traceability

Blogs, Pharmacovigilance, Regulatory /

In the realm of healthcare, patients have a fundamental right to transparency and information regarding the procedures they undergo particularly with respect to medical devices used for surgical procedures. One often overlooks the aspect of this right which is the traceability labels for medical devices used in surgical procedures regardless of whether the device is […]

Asserting Patient Rights: The Importance of Labels for Medical Device Traceability Read More »

Submitting Revised ANDA Labels to Ensure Safety & Compliance

Blogs, Regulatory /

Regulatory scrutiny for abbreviated new drug applications (ANDAs) places a strong focus on the accuracy and completeness of ANDA labels. Not only does this provide comprehensive information to healthcare professionals, but it also communicates information on medication usage and potential risks to ensure patients get clear and detailed information. This meticulous review process highlights the

Submitting Revised ANDA Labels to Ensure Safety & Compliance Read More »

Development of CAR T Cell Products

Blogs, Clinical Regulatory, Regulatory /

Chimeric antigen receptor (CAR) T cell products refer to therapeutic human gene therapy products. They involve the genetic modification of T cell specificity which allows them to recognize a specific target antigen for therapeutic use.  CAR T cells are associated with many challenges related to their development, manufacturing, testing, and even clinical evaluation. Therefore, it

Development of CAR T Cell Products Read More »

Model-Integrated Evidence Program for Generic Drugs

Blogs, Regulatory /

Timely patient access to affordable treatment options is the goal of healthcare and regulatory agencies worldwide. To support this, early and frequent communication between drug applicants and regulatory agencies is required to expedite generic drug development and approval. Streamlined communication allows a better and clearer understanding of regulatory expectations and facilitates a more efficient application

Model-Integrated Evidence Program for Generic Drugs Read More »

Searchable Databases for Bio-Equivalence Guidance

Blogs, Medical Writing, Regulatory /

Product-specific bioequivalence guidelines are crucial to support the development of safe, efficacious, and high-quality generic products. They provide information to manufacturers on how they can demonstrate therapeutic equivalence of their products compared to the reference drugs. Adherence to these guidelines streamline the regulatory approval process while also ensuring confidence with respect to the interchangeability of

Searchable Databases for Bio-Equivalence Guidance Read More »

banner_image

Increasing Harmonization for Complex Generics

Blogs, Regulatory /

Regulatory agencies across the globe are increasing their efforts in advancing the development of complex generics to facilitate patient and/or consumer access to safe, efficacious, and high-quality generic medicines. The generic medicine industry is already associated with many challenges such as declining profit margins and pricing making it a less attractive industry for generic pharmaceutical

Increasing Harmonization for Complex Generics Read More »

Regulatory Roadmap for Access to MedTech

Blogs, Medical Device, Regulatory /

In an era driven by technological advancements, particularly in healthcare, the need to implement a robust regulatory framework is more than ever to ensure compliance and patient safety. Indeed technological disruptors such as implantable medical devices, artificial intelligence, software, and diagnostics play a crucial role in healthcare whether they facilitate early detection or prevent complex

Regulatory Roadmap for Access to MedTech Read More »

Fostering Medical Innovation with Expedited Review Processes

Blogs, Regulatory /

2023 marked a significant year in the pharmaceutical industry as the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved an impressive 55 novel drugs. These approvals, including new molecular entities (NMEs) and new therapeutic biologics, underscore the FDA’s commitment to advancing patient care with innovative therapies. Over

Fostering Medical Innovation with Expedited Review Processes Read More »

Easing Requirements for Minimal Risk Clinical Trials

Blogs, Clinical Regulatory, Regulatory /

Expediting clinical trials that post minimal risk is important to advance healthcare & drug development. In particular, easing the requirements for informed consent regarding trial participants- for minimal risk clinical trials- can help expedite the entire clinical development process and ultimately accelerate the overall regulatory approval process. Earlier the US FDA’s regulations allowed for exceptions

Easing Requirements for Minimal Risk Clinical Trials Read More »

Standardizing Real World Data for Drug and Biological Product Submissions

Blogs, Regulatory /

Real world data (RWD) is proving to be an important source of information for applications such as New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), biologic license applications (BLAs) and Investigational New Drug (IND) applications. With RWD being submitted as relevant “study data”, certain agencies like the US FDA, require that the format should

Standardizing Real World Data for Drug and Biological Product Submissions Read More »